NCT04107584

Brief Summary

Hypertension is the most important risk factor for cardiovascular and cerebrovascular diseases，and also a substantial public health problem. The purpose of the study is to investigate the association between plasma biomarkers and adverse outcomes in patients with hypertension.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2017

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

September 26, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 27, 2019

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2022

Completed
Last Updated

September 27, 2019

Status Verified

September 1, 2019

Enrollment Period

5.3 years

First QC Date

September 26, 2019

Last Update Submit

September 26, 2019

Conditions

Hypertension

Outcome Measures

Primary Outcomes (1)

  • Primary mortality of hypertension

    The incidence rate of primary mortality of hypertension

    Through study completion, an average of 2 years

Secondary Outcomes (4)

  • Secondary outcomes of heart

    Through study completion, an average of 2 years

  • Secondary outcomes of brain

    Through study completion, an average of 2 years

  • Secondary outcomes of kidney

    Through study completion, an average of 2 years

  • Secondary outcomes of eyes

    Through study completion, an average of 2 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Hospitalized patients with hypertension

You may qualify if:

  • \>18 years old
  • In accordance with the diagnosis of hypertension (BP≥140/90mmHg)

You may not qualify if:

  • Pregnancy, history of heart failure or left ventricular ejection fraction less than 40%, myocardial infarction within one month, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting, cerebrovascular disease, severe liver disease, severe chronic renal failure (eGFR less than 30 mL/min/1.73 m2) in the past three months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Anzhen Hospital

Beijing, Beijing Municipality, 100029, China

RECRUITING

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Jie Du, PhD

    Beijing Anzhen Hospital

    STUDY DIRECTOR

Central Study Contacts

Yulin Li, PhD

CONTACT

0086-010-64456453lyllyl_1111@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 26, 2019

First Posted

September 27, 2019

Study Start

April 1, 2017

Primary Completion

August 1, 2022

Study Completion

August 1, 2022

Last Updated

September 27, 2019

Record last verified: 2019-09

Locations

CN(1)